People given injectable long-acting cabotegravir (CAB-LA; Apretude, ViiV Healthcare) as pre-exposure prophylaxis (PrEP) for HIV have higher levels of medication adherence than oral PrEP users.
However, real-world data about adherence to PrEP with CAB-LA presented at CROI 2024, held in Denver, suggest that although adherence rates are good, some patients miss injection appointments. Laurence Brunet, PhD, the senior director of epidemiology at Epividian in Raleigh, N.C., who